Lyell Immunopharma LYEL Q1 2026 Earnings Narrower Loss Beats Estimates as Biotech Advances Pipeline VELO Q1 2026 Earnings NarrowerthanExpected Loss Drives DoubleDigit Stock Surge MAT Q1 2026 Earnings NarrowerthanExpected Loss Drives Modest Stock Uptick RLMD Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Continues RD Investment Sweetgreen Q1 2026 Earnings EPS Misses Estimates Yet Stock Gains on Operational Momentum NATR Q1 2026 Earnings Strong EPS Surprise Amid Quiet Revenue Disclosures